Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Juris J Meier

Showing results (21-30 of 144) with videos related to

Pageof 15
Sort By:
Scientific Reports|December 6, 2022
Statistical power for MACE and individual secondary endpoints in cardiovascular outcomes trials for type 2 diabetes: a systematic reviewSebastian Birker, Juris J Meier, Michael A Nauck
Pediatric Research|March 22, 2006
The potential for stem cell therapy in diabetesJuris J Meier, Anil Bhushan, Peter C Butler
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 19, 2003
Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitusJuris J Meier, Baptist Gallwitz, Michael A Nauck
Diabetes, Obesity & Metabolism|April 9, 2020
Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programmeTina K Thethi, Richard Pratley, Juris J Meier
Drug News & Perspectives|December 12, 2003
Incretins and their analogues as new antidiabetic drugsMichael A Nauck, Juris J Meier, Werner Creutzfeldt
The Lancet. Diabetes & Endocrinology|June 28, 2021
Treatment of type 2 diabetes: challenges, hopes, and anticipated successesMichael A Nauck, Jakob Wefers, Juris J Meier
Diabetes|November 25, 2004
Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetesMichael A Nauck, Birgit Baller, Juris J Meier
Diabetes & Metabolism Journal|March 22, 2022
Comparison of Insulin-Treated Patients with Ambiguous Diabetes Type with Definite Type 1 and Type 2 Diabetes Mellitus Subjects: A Clinical PerspectiveInsa Laspe, Juris J Meier, Michael A Nauck
Diabetes Care|September 10, 2020
Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysisJessica A Huthmacher, Juris J Meier, Michael A Nauck
American Journal of Physiology. Endocrinology and Metabolism|February 3, 2011
Diminished glucagon suppression after β-cell reduction is due to impaired α-cell function rather than an expansion of α-cell massJuris J Meier, Sandra Ueberberg, Simone Korbas, et al.
Pageof 15

Showing results (21-30 of 144) with videos related to

Sort By:
Pageof 15
Scientific Reports|December 6, 2022
Statistical power for MACE and individual secondary endpoints in cardiovascular outcomes trials for type 2 diabetes: a systematic reviewSebastian Birker, Juris J Meier, Michael A Nauck
Pediatric Research|March 22, 2006
The potential for stem cell therapy in diabetesJuris J Meier, Anil Bhushan, Peter C Butler
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 19, 2003
Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitusJuris J Meier, Baptist Gallwitz, Michael A Nauck
Diabetes, Obesity & Metabolism|April 9, 2020
Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programmeTina K Thethi, Richard Pratley, Juris J Meier
Drug News & Perspectives|December 12, 2003
Incretins and their analogues as new antidiabetic drugsMichael A Nauck, Juris J Meier, Werner Creutzfeldt
The Lancet. Diabetes & Endocrinology|June 28, 2021
Treatment of type 2 diabetes: challenges, hopes, and anticipated successesMichael A Nauck, Jakob Wefers, Juris J Meier
Diabetes|November 25, 2004
Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetesMichael A Nauck, Birgit Baller, Juris J Meier
Diabetes & Metabolism Journal|March 22, 2022
Comparison of Insulin-Treated Patients with Ambiguous Diabetes Type with Definite Type 1 and Type 2 Diabetes Mellitus Subjects: A Clinical PerspectiveInsa Laspe, Juris J Meier, Michael A Nauck
Diabetes Care|September 10, 2020
Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysisJessica A Huthmacher, Juris J Meier, Michael A Nauck
American Journal of Physiology. Endocrinology and Metabolism|February 3, 2011
Diminished glucagon suppression after β-cell reduction is due to impaired α-cell function rather than an expansion of α-cell massJuris J Meier, Sandra Ueberberg, Simone Korbas, et al.
Pageof 15